Please assess the completion status of the following clinical trial:

Trial Title: Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 6-12 years old~* ADHD diagnosis~* ADHD-RS-IV minimum score of 28~* CGI-S score \> or = 4~Exclusion Criteria:~* Current, controlled or uncontrolled, comorbid psychiatric diagnosis~* Condition or illness which represent inappropriate risk to subject~* Known history or presence of structural cardiac abnormalities, serious heart rhythm abnormalities, syncope, cardiac conduction problems, exercise-related cardiac events, or clinically significant bradycardia; orthostatic hypotension or controlled or uncontrolled hypertension~* Use of prohibited medication that have CNS effects or affect cognitive performance~* History of alcohol or substance abuse within 6 months~* Current use of medication that affect BP or heart rate~* Significantly overweight~* Weight of less than 55 lbs~* Known allergy to SPD503~* Abnormal urine drug and alcohol screen

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Extended-release Guanfacine Hydrochloride (SPD503) AM (Type: EXPERIMENTAL): None
- placebo (Type: EXPERIMENTAL): None
- SPD503 PM (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).